The topics in this session include US regulatory environment & alternative pathways (including next steps,  if already achieved US clearance), levels of clinical evidence, economic outcomes.

Speakers: 

• Kristi Nakayama, Veranex
• Carmen Brown, Proxima
• Nicolle Cannon, CQG